EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch

Jian-Ge Qiu, Peng Sang, Feng-Mei Zhou, Xiao-Qi Zhang, Wei Wang, Ying-Chen Qian, Ye Zhang, Lin Wang, Ling-Zhi Liu, You-Qiu Xue, Xin Zhao, Qiang Shan und 3 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.218035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Jian-Ge Qiu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Department of Clinical Research and Translational Medicine, The Third Affiliated Hospital of Zhengzhou University, State Key…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Ribonucleoproteins, Neoplasms, Tumor-Associated Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Henan Provincial Department of Transportation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor microenvironment (TME) plays a pivotal role in cancer progression, though the molecular regulators governing its immunosuppressive properties remain incompletely characterized. In this study, we identify Makorin-2 (MKRN2) as a novel modulator of TME remodeling through integrated analyses of genetically engineered mouse models and human clinical data. Utilizing MKRN2 knockout mice, we observed significantly accelerated tumor growth compared to wild-type control, which was associated with profound alterations in immune cell composition, especially M2 macrophages. Specifically, MKRN2 deficiency promoted a phenotypic switch in tumor-associated macrophages (TAMs) from anti-tumor M1 to pro-tumorigenic M2 polarization, with quantitative analysis revealing a 3-fold increase in the M2:M1 ratio. Clinical correlation studies demonstrated that MKRN2 expression was frequently downregulated across multiple human malignancies, with low MKRN2 levels strongly correlating with advanced disease stage and reduced patient survival. Mechanistic investigations revealed a dual regulatory mechanism of MKRN2 downregulation: epigenetic silencing through promoter CpG methylation and post-transcriptional suppression by oncogenic miR-582-5p. At the molecular level, MKRN2 functioned as an E3 ubiquitin ligase that directly targeted NF-κB p65 for proteasomal degradation, thereby constraining NF-κB/COX2-mediated inflammatory signaling. Reconstitution experiments demonstrated that MKRN2 overexpression significantly inhibited tumor cell proliferation, migration/invasion and tumor growth. Our findings establish MKRN2 as a critical regulator of immunosuppressive TME formation through coordinated control of macrophage polarization and NF-κB/COX2 signaling, suggesting its potential as both a prognostic biomarker and therapeutic target for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentRibonucleoproteinsNeoplasmsTumor-Associated MacrophagesMacrophagesAnimalsHumansMice, KnockoutMiceCell ProliferationGene Expression Regulation, NeoplasticMicroRNAsCell Line, TumorUbiquitin-Protein LigasesDNA MethylationTranscription Factor RelAFemaleSignal TransductionCyclooxygenase 2

Stichwörter der Autor:innen

COX2CancerMKRN2NF-κBTumor immune microenvironment

Substanzen

RibonucleoproteinsMicroRNAsUbiquitin-Protein LigasesTranscription Factor RelACyclooxygenase 2

Autor:innen und Institutionen

  • Department of Radiology, Department of Clinical Research and Translational Medicine, The Third Affiliated Hospital of Zhengzhou University, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of E…
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052,…
  • Pathology Department, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing Jiangning Hospital, Nanjing Medical University, Nanjing, 210000, China.
  • Department of Gynecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou University, Zhengzhou, 450008, China.
  • Department of Immunology, School of Cell and Gene Therapy, Songjiang Research Institute and Songjing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 201600, China.
  • National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, 215123, China.

Förderung

  • National Natural Science Foundation of China
  • Henan Provincial Department of Transportation

Zitieren

APA

Qiu, J. G., Sang, P., Zhou, F. M., Zhang, X. Q., Wang, W., Qian, Y. C., Zhang, Y., Wang, L., Liu, L. Z., Xue, Y. Q., Zhao, X., Shan, Q., Huang, P., Zheng, S. G., & Jiang, B. H. (2025). Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218035

Vancouver

Qiu JG, Sang P, Zhou FM, Zhang XQ, Wang W, Qian YC, et al. Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218035

BibTeX
@article{Qiu2025,
  author = {Qiu, Jian-Ge and Sang, Peng and Zhou, Feng-Mei and Zhang, Xiao-Qi and Wang, Wei and Qian, Ying-Chen and Zhang, Ye and Wang, Lin and Liu, Ling-Zhi and Xue, You-Qiu and Zhao, Xin and Shan, Qiang and Huang, Peng and Zheng, Song Guo and Jiang, Bing-Hua},
  title = {Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.218035}
}
Kostenlos starten →